Key regions: United Kingdom, Germany, France, South Korea, Italy
Moldova, a small landlocked country in Eastern Europe, has been making strides in the COVID-19 vaccines market. The country has been able to secure a steady supply of vaccines, and the vaccination campaign has been progressing steadily.
Customer preferences: The Moldovan population has shown a high level of interest in receiving the COVID-19 vaccine. The government has been actively promoting vaccination and has made it free and accessible to all citizens. This has resulted in a high demand for vaccines, which has been met by a steady supply.
Trends in the market: Moldova has been able to secure vaccines from several different sources, including the COVAX facility, the European Union, and bilateral agreements with other countries. This has allowed the country to have a diversified vaccine portfolio, which has helped to mitigate supply chain risks. Additionally, the government has been actively working to increase the number of vaccination sites and has been conducting outreach campaigns to encourage more people to get vaccinated.
Local special circumstances: Moldova has a relatively small population and a low GDP per capita compared to other European countries. However, the country has been able to secure a steady supply of vaccines and has been making progress in its vaccination campaign. This can be attributed to the government's proactive approach to securing vaccines and promoting vaccination.
Underlying macroeconomic factors: Moldova's economy has been heavily impacted by the COVID-19 pandemic, with a sharp decline in GDP and a rise in unemployment. However, the government has been working to mitigate the economic impact of the pandemic through various measures, including financial support for businesses and individuals. The successful vaccination campaign is expected to have a positive impact on the economy by reducing the spread of the virus and allowing businesses to reopen.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
